30 July 2024

MaxRets Ventures PLC

("MaxRets" or the "Company")

Unaudited Interim Results for the six months ended 30 April 2024

MaxRets Ventures plc (the "Company" or "MaxRets"), an investing company focusing on early-stage or undervalued later stage businesses with strong upside potential, today announces its unaudited interim results for the six months ended 30 April 2024.

This announcement contains inside information for the purpose of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information please contact:

Chairman's Strategic and Financial Review

MaxRets is an investment company quoted on the Access Segment of the Aquis Stock Exchange ("AQSE") Growth Market, the successor to the NEX Exchange Growth Market ("NEX"). The Company was incorporated on 1st October 2019 and its shares were admitted to trading on NEX on 30 December 2019.

The Company's strategy is to invest in technology driven businesses based on their potential for future value enhancement and overall investment return.  It follows a growth incubator and pre-IPO investment philosophy whereby it seeks out early stage or undervalued later stage businesses with strong upside potential, with the objective of acquiring, funding, growing, and selling-on investments through the public market at enhanced valuations.

The Board will not restrict the jurisdiction of investments since the application of technology is not constrained by geographic borders.

The Company will invest directly or indirectly in public or private companies and may take the form of debt or equity and it is expected that such investments will ordinarily seek capital growth in the medium term in preference to income.

MaxRets continues to own two legacy investments in the cannabis sector that were both made in 2021.

The first investment in March 2021 was a £100,000 investment in Clearly Supplements Ltd. ("Clearly") a UK based company offering CBD products direct to customers. The investment was by way of a convertible loan note ("CLN") which was expected to convert at the time of a public listing at a 30 per cent. discount to the placing price.  However, given changes in market conditions they have decided not to proceed with a listing and are now seeking a strategic private equity partnership.

As we noted at the time of the full year results to 31 October 2023, Clearly has challenging trading conditions in a market that has not developed as was hoped. Given the lack of progress made by Clearly the Maxrets board wrote down the investment to nil in the year to 31 October 2023.

The second was an equity investment of £100,000 in Voyager Life plc ("Voyager"), a health and wellness business focused on CBD and hemp seed oil, that has developed a range of products under the  Voyager and Voyager Life brands, including oils, gummies, bath and skincare products.  Voyager completed an IPO on the AQSE market in June 2021, resulting in the Company holding approximately 2.8% of the issued share capital at the time of flotation. At the time of our full year results to 31 October 2023 we reported that Voyager had been unable to complete a corporate acquisition and associated fundraise and as a result the Board decided to write down it's investment in Voyager plc to nil.

Since that point Voyager has changed direction, securing an option to acquire M3 Helium Corp. in Kansas USA, a business that produces helium gas for the US market, and at the same time having raised approximately £864k in additional funding. We are pleased to see the company recapitalised.

Outlook

The market outlook for technology driven investments remains positive.

The Directors are of the opinion that there are exciting investment opportunities in those market sectors which the Company is   focused upon.

The Board is constantly assessing potential transactions and looks forward to updating the market further in the near future.

Dominic White

Non-executive Chairman 30 July 2024